• Explore /
  • Poster
  • / Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.

Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.

Abstract Poster

Authors

null

Andres Poveda

Clinical Area of Gynecologic Oncology, Instituto Valenciano de Oncología (IVO), Valencia, Spain

Andres Poveda , Ana Oaknin , Ignacio Romero , Angel Guerrero , Lorena Fariñas-Madrid , Victor Rodriguez-Freixinos , Arturo Soto-Matos , Carlos Peris , Marisa Teruel , Raquel Lopez-Reig , Jose Antonio Lopez-Guerrero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02684318

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5573)

DOI

10.1200/JCO.2017.35.15_suppl.5573

Abstract #

5573

Poster Bd #

395

Abstract Disclosures

Similar Posters

First Author: Ecaterina Elena Dumbrava

First Author: Junning Cao

First Author: Andrew J. Wagner

First Author: Sarina Anne Piha-Paul